Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored preoperative analgesic therapy and lymphocyte opioid receptor biomarkers in hip arthroplasty
ISRCTN12559751Phase 4Completed
- Sponsor
- ISAL Foundation
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tapentadol, acetaminophen and caffeine in osteoarthritis (OA) and osteonecrosis of the hip (3 arms), sponsored by ISAL Foundation. Primary endpoints: Lymphocyte opioid receptor expression and function and Bone marrow morphology and morphometry. Started Dec 2016; status: completed.
02
Drugs
tapentadolacetaminophencaffeine
03
Conditions
osteoarthritis (OA)osteonecrosis of the hip
Beyond the preview
Go deeper on ISRCTN12559751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12559751.